Global Longlife Hospital and Research Ltd
Incorporated in 2015, Global Longlife Hospital & Research Ltd is a Multispecialty Hospital providing Medical & Allied Services
- Market Cap ₹ 33.6 Cr.
- Current Price ₹ 32.0
- High / Low ₹ 61.7 / 27.0
- Stock P/E
- Book Value ₹ 25.9
- Dividend Yield 0.00 %
- ROCE -2.51 %
- ROE -4.72 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Debtor days have improved from 102 to 52.9 days.
- Company's working capital requirements have reduced from 161 days to 14.6 days
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -16.6% over past five years.
- Company has a low return on equity of 3.28% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|
33.44 | 33.32 | 32.70 | 32.44 | 23.38 | 13.46 | 1.76 | |
26.61 | 29.88 | 27.26 | 24.14 | 19.30 | 13.68 | 8.59 | |
Operating Profit | 6.83 | 3.44 | 5.44 | 8.30 | 4.08 | -0.22 | -6.83 |
OPM % | 20.42% | 10.32% | 16.64% | 25.59% | 17.45% | -1.63% | -388.07% |
0.08 | 0.03 | 0.06 | 0.17 | 0.24 | 0.00 | 5.73 | |
Interest | 2.07 | 2.41 | 2.44 | 1.62 | 0.45 | 0.80 | 0.64 |
Depreciation | 2.15 | 2.13 | 1.31 | 1.14 | 1.17 | 1.25 | 1.12 |
Profit before tax | 2.69 | -1.07 | 1.75 | 5.71 | 2.70 | -2.27 | -2.86 |
Tax % | 49.07% | -18.69% | -16.57% | 37.30% | 32.59% | -3.52% | |
1.36 | -0.86 | 2.05 | 3.57 | 1.83 | -2.19 | -1.98 | |
EPS in Rs | 1.94 | -1.23 | 2.93 | 5.10 | 1.74 | -2.09 | -1.89 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -17% |
3 Years: | -26% |
TTM: | -93% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -194% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -24% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 4% |
3 Years: | 3% |
Last Year: | -5% |
Balance Sheet
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|
Equity Capital | 7.00 | 7.00 | 7.00 | 7.00 | 10.50 | 10.50 | 10.50 |
Reserves | 5.35 | 4.49 | 6.68 | 9.96 | 53.79 | 15.43 | 16.67 |
27.18 | 23.51 | 17.04 | 8.69 | 9.29 | 12.74 | 0.00 | |
3.77 | 6.92 | 6.06 | 8.33 | 2.36 | 3.07 | 0.20 | |
Total Liabilities | 43.30 | 41.92 | 36.78 | 33.98 | 75.94 | 41.74 | 27.37 |
20.17 | 18.72 | 17.46 | 16.71 | 16.52 | 17.27 | 0.00 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 1.03 | 0.00 | 0.00 |
Investments | 0.10 | 0.10 | 0.47 | 0.10 | 0.10 | 0.03 | 18.67 |
23.03 | 23.10 | 18.85 | 17.17 | 58.29 | 24.44 | 8.70 | |
Total Assets | 43.30 | 41.92 | 36.78 | 33.98 | 75.94 | 41.74 | 27.37 |
Cash Flows
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
5.40 | 3.90 | 6.88 | 9.42 | -40.42 | -5.07 | |
-0.33 | -0.04 | 0.02 | 0.01 | -1.90 | -0.82 | |
-4.77 | -3.05 | -7.22 | -9.66 | 45.70 | 2.67 | |
Net Cash Flow | 0.31 | 0.81 | -0.33 | -0.22 | 3.38 | -3.22 |
Ratios
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Debtor Days | 94.85 | 68.68 | 87.51 | 100.25 | 151.43 | 52.88 |
Inventory Days | 169.49 | 157.97 | 34.46 | 88.98 | 69.12 | 131.64 |
Days Payable | 229.91 | 391.69 | 138.68 | 432.74 | 110.43 | 765.90 |
Cash Conversion Cycle | 34.44 | -165.03 | -16.71 | -243.52 | 110.13 | -581.38 |
Working Capital Days | 82.85 | 78.21 | 57.82 | 36.34 | 433.07 | 14.64 |
ROCE % | 3.81% | 12.75% | 26.22% | 6.35% | -2.51% |
Documents
Announcements
-
Board Meeting Outcome for Financial Results For The Half Year Ended On September 30, 2024 Along With Limited Review Report
28 Oct - Approval of unaudited financial results for H1 2024.
-
Board Meeting Outcome for Financial Results For The Half Year Ended On September 30, 2024 Along With Limited Review Report
28 Oct - Approval of unaudited financial results for H1 2024.
-
Financial Results For The Half Year Ended On September 30, 2024 Along With Limited Review Report
28 Oct - Approval of unaudited financial results for H1 2024.
-
Board Meeting Intimation for Consideration Of Unaudited Financial Results For The Half Year Ended On September 30, 2024 And Other Matters
22 Oct - Board meeting to consider unaudited financial results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
19 Oct - Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2024 received from Bigshare Services Private Limited, RTA of the …
Business Overview:[1]
Company is a Multi Speciality Tertiary Care Hospital of Gujarat with 110 beds equipped for Medical & Surgical specialties. Company is certified by National Accreditation Board for Hospitals and Healthcare Providers (NABH)